ANIX
Income statement / Annual
Last year (2024), Anixa Biosciences, Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2024, Anixa Biosciences, Inc.'s net income was -$12.55 M.
See Anixa Biosciences, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
10/31/2024 |
10/31/2023 |
10/31/2022 |
10/31/2021 |
10/31/2020 |
10/31/2019 |
10/31/2018 |
10/31/2017 |
10/31/2016 |
10/31/2015 |
| Operating Revenue |
$0.00 |
$210.00 K |
$2.47 B |
$512.50 K |
$0.00 |
$250.00 K |
$1.11 M |
$362.50 K |
$300.00 K |
$9.26 M |
| Cost of Revenue |
$37.00 K
|
$161.00 K
|
$42.00 K
|
$385.00 K
|
$90.16 K
|
$166.25 K
|
$768.41 K
|
$104.56 K
|
$217.42 K
|
$3.65 M
|
| Gross Profit |
-$37.00 K
|
$49.00 K
|
$2.47 B
|
$127.50 K
|
-$90.16 K
|
$83.75 K
|
$344.09 K
|
$257.94 K
|
$82.58 K
|
$5.61 M
|
| Gross Profit Ratio |
0
|
0.23
|
1
|
0.25
|
0
|
0.34
|
0.31
|
0.71
|
0.28
|
0.61
|
| Research and Development Expenses |
$6.40 M
|
$4.77 M
|
$6.70 M
|
$6.19 M
|
$4.38 M
|
$5.47 M
|
$6.81 M
|
$1.60 M
|
$1.56 M
|
$711.39 K
|
| General & Administrative Expenses |
$7.44 M
|
$6.29 M
|
$7.17 M
|
$7.07 M
|
$5.60 M
|
$5.66 M
|
$6.91 M
|
$4.41 M
|
$2.71 M
|
$5.51 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$7.44 M
|
$6.29 M
|
$7.17 M
|
$7.07 M
|
$5.60 M
|
$5.66 M
|
$6.91 M
|
$4.41 M
|
$2.71 M
|
$5.51 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$418.75 K
|
$0.00
|
-$13.10 K
|
$0.00
|
$0.00
|
| Operating Expenses |
$13.83 M
|
$11.06 M
|
$13.88 M
|
$13.26 M
|
$9.98 M
|
$11.56 M
|
$14.05 M
|
$6.33 M
|
$4.59 M
|
$6.55 M
|
| Cost And Expenses |
$13.83 M
|
$11.22 M
|
$13.88 M
|
$13.65 M
|
$9.98 M
|
$11.72 M
|
$14.82 M
|
$6.44 M
|
$4.81 M
|
$10.20 M
|
| Interest Income |
$1.13 M
|
$1.08 M
|
$104.00 K
|
$2.32 K
|
$33.92 K
|
$71.35 K
|
$45.97 K
|
$19.44 K
|
$12.53 K
|
$17.62 K
|
| Interest Expense |
$0.00
|
$0.00
|
$104.00 K
|
$322.00
|
$0.00
|
$0.00
|
$0.00
|
$500.46 K
|
$519.95 K
|
$451.91 K
|
| Depreciation & Amortization |
$37.00 K
|
$46.00 K
|
$42.00 K
|
$59.86 K
|
$90.16 K
|
$466.31 K
|
$343.73 K
|
$368.51 K
|
$358.63 K
|
$337.81 K
|
| EBITDA |
-$12.66 M |
-$10.97 M |
-$13.73 M |
-$13.08 M |
-$10.00 M |
-$11.00 M |
-$13.36 M |
-$4.14 M |
-$4.14 M |
-$601.85 K |
| EBITDA Ratio |
0
|
-52.21
|
-0.01
|
-25.52
|
0
|
-44.02
|
-12.01
|
-11.42
|
-13.79
|
-0.07
|
| Operating Income Ratio |
0
|
-52.43
|
-0.01
|
-25.63
|
0
|
-45.89
|
-12.84
|
-16.76
|
-15.03
|
-0.1
|
| Total Other Income/Expenses Net |
$1.13 M
|
$1.08 M
|
$104.00 K
|
-$173.60 K
|
-$114.16 K
|
$71.35 K
|
$45.97 K
|
$1.07 M
|
-$507.42 K
|
-$434.28 K
|
| Income Before Tax |
-$12.70 M
|
-$9.93 M
|
-$13.77 M
|
-$13.31 M
|
-$10.09 M
|
-$11.82 M
|
-$14.24 M
|
-$5.01 M
|
-$5.02 M
|
-$1.38 M
|
| Income Before Tax Ratio |
0
|
-47.29
|
-0.01
|
-25.97
|
0
|
-47.27
|
-12.8
|
-13.82
|
-16.72
|
-0.15
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
-$181.29 K
|
$0.00
|
$175.80 K
|
$0.00
|
$0.00
|
$12.53 K
|
$0.00
|
| Net Income |
-$12.55 M
|
-$9.81 M
|
-$13.49 M
|
-$12.95 M
|
-$10.13 M
|
-$11.99 M
|
-$14.00 M
|
-$5.01 M
|
-$5.02 M
|
-$1.38 M
|
| Net Income Ratio |
0
|
-46.72
|
-0.01
|
-25.26
|
0
|
-47.98
|
-12.58
|
-13.82
|
-16.72
|
-0.15
|
| EPS |
-0.39 |
-0.32 |
-0.44 |
-0.45 |
-0.46 |
-0.61 |
-0.79 |
-0.41 |
-0.57 |
-0.14 |
| EPS Diluted |
-0.39 |
-0.32 |
-0.44 |
-0.45 |
-0.46 |
-0.61 |
-0.79 |
-0.41 |
-0.57 |
-0.14 |
| Weighted Average Shares Out |
$31.90 M
|
$30.98 M
|
$30.37 M
|
$28.58 M
|
$22.23 M
|
$19.79 M
|
$17.62 M
|
$12.20 M
|
$8.74 M
|
$9.63 M
|
| Weighted Average Shares Out Diluted |
$31.90 M
|
$30.98 M
|
$30.37 M
|
$28.58 M
|
$22.23 M
|
$19.79 M
|
$17.62 M
|
$12.20 M
|
$8.74 M
|
$9.63 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
